The best current conclusion is that hypnotherapy for depression remains investigational rather than guideline-established. Some randomized trials report meaningful symptom improvement, but the overall evidence is small, heterogeneous, and generally too uncertain to support routine use—especially as a replacement for antidepressants or established psychotherapies.
What the evidence shows
A 2024 systematic review focused specifically on randomized trials in adults with diagnosed major depressive disorder found very-low-quality evidence that hypnosis-based interventions may reduce depressive severity. The authors concluded that the evidence does not currently justify clinical use and that better trials are needed to establish effectiveness and safety.[1]
An earlier systematic review of randomized controlled trials identified only four eligible trials. Although results generally favored hypnotherapy, only one trial had low risk of bias; that study found hypnotherapy non-inferior to cognitive behavioral therapy (CBT) for mild-to-moderate depression.[9]
A more recent randomized trial involving 152 people with mild-to-moderate major depression also reported that hypnotherapy was non-inferior to CBT, although the average symptom reduction was approximately 38% and many participants did not improve.[10]
A 2024 scoping review found only 14 relevant studies after screening 232 records, ranging from case reports to randomized trials. It described promising findings but emphasized the need for better-controlled research before efficacy can be established.[2]
A broad 2024 review of hypnosis meta-analyses found beneficial effects across various mental and physical health conditions, but it was not specific to depression; therefore, its overall findings should not be interpreted as proof that hypnotherapy treats major depressive disorder.[5]
Why confidence remains low
The studies differ substantially in:
The type of hypnosis used, including cognitive hypnotherapy, adjunctive hypnosis, and self-hypnosis
Whether hypnosis was used alone or alongside CBT, medication, or usual care
Depression severity and diagnostic criteria
Number and duration of sessions
Depression measurement scales and follow-up periods
Control conditions and ability to blind participants
Small samples, inconsistent treatment protocols, limited long-term follow-up, and risk of bias make it difficult to determine whether improvement comes from hypnosis itself, therapeutic attention, expectancy, or concurrent treatment.[1][3][4]
Current clinical interpretation
Hypnotherapy may be considered an adjunct—not a substitute—for evidence-based depression treatment, particularly for selected adults with mild-to-moderate symptoms who are interested in it and are treated by a qualified licensed mental-health professional. The available evidence does not support using it alone for severe depression, psychotic depression, bipolar depression, active suicidality, or treatment-resistant depression.
The 2024 Swedish health-technology assessment identified relevant systematic reviews but noted that several had high risk of bias and therefore could not support firm conclusions.[4] The 2024 systematic review likewise stated that new research is very likely to change the estimated effects.[1] No robust 2024–2025 evidence located here establishes hypnotherapy as a recommended first-line treatment in depression guidelines.
Practical recommendation
Continue or seek established treatments such as CBT, behavioral activation, interpersonal therapy, antidepressant medication when clinically appropriate, or a combination.
If hypnosis is added, use a clinician with recognized mental-health credentials and formal hypnosis training.
Clarify whether the intervention is adjunctive, how improvement will be measured, and when treatment will be reassessed.
Do not stop antidepressants or psychotherapy abruptly because of hypnotherapy.
Seek urgent help for suicidal thoughts, inability to stay safe, psychosis, or rapidly worsening symptoms; hypnosis is not an emergency treatment.
Bottom line: Hypnotherapy is a plausible complementary intervention with encouraging but preliminary trial findings. As of the available 2024–2025 evidence, the certainty is too low for routine guideline recommendation, and established treatments should remain the foundation of care.[1][4][9]
Sources: